Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: November 15, 2024
Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 01, 2024
Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
Journal: The New England journal of medicine
Published: July 17, 2024
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
Journal: The New England journal of medicine
Published: April 10, 2024
Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
Journal: The New England journal of medicine
Published: September 07, 2022
Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 29, 2022
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Journal: The New England journal of medicine
Published: February 16, 2022
Showing 1-7 of 7
Last Updated: 09/26/2026